WEBULL
News
CERS
2.240
+3.23%
0.070
Weekly Report: what happened at CERS last week (0202-0206)?
Weekly Report · 5d ago
Cerus’ INTERCEPT Platelet Trial Nears Data Phase: Reading the Signals for Investors
TipRanks · 02/06 16:30
Weekly Report: what happened at CERS last week (0126-0130)?
Weekly Report · 02/02 09:37
Weekly Report: what happened at CERS last week (0119-0123)?
Weekly Report · 01/26 09:38
Cerus Director Timothy L. Moore to Step Down After Current Term
Reuters · 01/26 07:30
Cerus announces planned board transition as director departs
TipRanks · 01/23 22:21
Analysts Are Bullish on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Cerus (CERS)
TipRanks · 01/23 16:51
DRK BLOOD DONATION SERVICE BADEN-WÜRTTEMBERG – HESSEN STARTS INITIATE STUDY TO EVALUATE PATHOGEN-INACTIVATED PLATELET CONCENTRATES TREATED WITH CERUS’ INTERCEPT™ BLOOD SYSTEM IN ROUTINE CLINICAL PRACTICE
Reuters · 01/22 12:30
DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus’ INTERCEPT™ Blood System in Routine Clinical Practice
Barchart · 01/22 06:30
Weekly Report: what happened at CERS last week (0112-0116)?
Weekly Report · 01/19 09:41
TG Therapeutics, Clover Health Investments, Nutrien And Other Big Stocks Moving Higher On Wednesday
Benzinga · 01/14 14:52
After-Hours Biotech Rally: SXTC, RPID, TGTX Lead Gains On Revenue Updates, And FDA Milestones
NASDAQ · 01/14 03:20
Cerus Corporation Forecasts 2026 Product Revenue of Up to $228 Million
Reuters · 01/12 13:07
Weekly Report: what happened at CERS last week (0105-0109)?
Weekly Report · 01/12 09:40
Cerus expects 14% jump in 2025 topline, guides 2026
Seeking Alpha · 01/12 07:35
Reported Earlier, Cerus Reports Preliminary 2025 Product Revenue Of $206.1M, Up 14% YoY; Guides 2026 Product Revenue Of $224M–$228M On 9%–11% Growth And IFC Revenue Of $20M–$22M
Benzinga · 01/12 07:34
Analysts Offer Insights on Healthcare Companies: Cerus (CERS) and Kura Oncology (KURA)
TipRanks · 01/12 03:10
Cerus sees FY26 product revenue $224M-$228M
TipRanks · 01/11 22:15
Cerus Corporation Projects 2026 Product Revenue of $224 Million to $228 Million
Reuters · 01/11 21:00
CERUS CORP: EXPECTS FULL-YEAR 2026 PRODUCT REVENUE TO BE IN THE RANGE OF $224 MILLION TO $228 MILLION
Reuters · 01/11 21:00
More
Webull provides a variety of real-time CERS stock news. You can receive the latest news about Cerus through multiple platforms. This information may help you make smarter investment decisions.
About CERS
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.